ArticleVaccine2026
Pneumococcal carriage among children and adults before and after a change from a three-dose 13-valent pneumococcal conjugate vaccine schedule without a booster to a two-dose schedule with a booster in Burkina Faso.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn June 2021, Burkina Faso changed the 13-valent pneumococcal conjugate vaccine (PCV13) schedule from three primary doses with no booster (at 2, 3, 4 months) (3 + 0) to two primary doses with a booster (at 2, 4, 9 months) (2 + 1), which may optimize vaccine impact due to a booster dose.
methodsWe conducted two cross-sectional, age-stratified (age 1-11 months [infants], 1 year, 2-4 years, 5-14 years, and ≥ 15 years) pneumococcal carriage surveys in Bobo-Dioulasso in April-May 2022 and March-April 2023 and compared results with one similar survey conducted in March 2020. We collected demographic and epidemiologic information, including vaccination history (participants aged <5 years), and one nasopharyngeal (all participants) and one oropharyngeal (participants aged ≥5 years) swab from participants. Pneumococci isolated by culture were serotyped by PCR (all isolates in 2020 and 2022) and/or Quellung (subset of isolates in 2020 and 2022, all isolates in 2023). We evaluated pneumococcal carriage before (2020), during transition (2022), and after (2023) the PCV13 schedule change.
resultsWe enrolled 1002, 1025, and 1007 participants in 2020, 2022, and 2023, respectively. Median age at dose 3 for 2 + 1-eligible children (infants in 2022 and children aged <2 years in 2023) was 4.3 months in 2022 and 9.1 months in 2023. From 2020 to 2023, PCV13-type carriage declined significantly among infants (2023: 9.5 % 2020: 19.0 %; adjusted prevalence ratio: 0.53, 95 % CI: 0.31-0.88) but not in other age groups.
conclusionsThe decline in PCV13-type carriage observed only in infants is likely unrelated to the PCV13 schedule change, since only those aged ≥9 months could have received a booster dose. Additional birth cohorts vaccinated with the 2 + 1 schedule are needed to understand the effects on PCV13-type carriage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.